# Shree Pacetroni (NSE: SHREEPAC) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/SHREEPAC · Pivot · prices to 22 Oct 2026

With a market capitalisation of ₹50 Cr, it ranks 3077th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Instruments & Supplies.

Its return on equity was 17.4% in FY26. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹5 Cr (+25.5% year on year) and net profit ₹1 Cr (+146.7%), on a consolidated basis. Promoters held 36.44% of the company as of 30 Jun 2026; 9.44% of promoter shares were pledged.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹50 Cr |
| ROE | 17.4% (FY26) |
| ROCE | 25.0% (FY26) |
| Debt to equity | 0.15 |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹5 Cr | +25.5% | ₹1 Cr | +146.7% | ₹3.06 |
| Q3 FY26 | ₹4 Cr | +19.3% | ₹0 Cr | — | ₹0.16 |
| Q2 FY26 | ₹7 Cr | +63.1% | ₹1 Cr | +4,266.7% | ₹3.64 |
| Q1 FY26 | ₹5 Cr | +10.1% | ₹1 Cr | +78.4% | ₹1.85 |
| Q4 FY25 | ₹4 Cr | −35.6% | ₹0 Cr | −68.5% | ₹1.26 |
| Q3 FY25 | ₹4 Cr | −15.6% | −₹0 Cr | −127.5% | −₹0.31 |
| Q2 FY25 | ₹4 Cr | −22.8% | ₹0 Cr | −95.5% | ₹0.09 |
| Q1 FY25 | ₹5 Cr | −17.2% | ₹0 Cr | −57.0% | ₹1.03 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹17 Cr | ₹1 Cr |
| FY24 | ₹22 Cr | ₹3 Cr |
| FY23 | ₹20 Cr | ₹3 Cr |
| FY22 | ₹9 Cr | ₹1 Cr |
| FY21 | ₹8 Cr | ₹0 Cr |
| FY20 | ₹9 Cr | ₹0 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 36.44%
- Non-institutions: 63.56%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Bandaram Pharma](https://app.pivotnow.in/stock/BANDARAM) | — | ₹53 Cr | — | — |
| [Vasundhara Ras](https://app.pivotnow.in/stock/VRL) | — | ₹53 Cr | — | — |
| [Vivimed Labs](https://app.pivotnow.in/stock/VIVIMEDLAB) | ₹6.21 | ₹51 Cr | — | — |
| [Biofil Chemicals & Pharmaceuticals](https://app.pivotnow.in/stock/BIOFILCHEM) | ₹30.00 | ₹49 Cr | 17.5 | — |
| [Shanmuga Hospit](https://app.pivotnow.in/stock/SHANMUGA) | — | ₹48 Cr | — | — |
| [Mangalam Drugs And Organics](https://app.pivotnow.in/stock/MANGALAM) | ₹29.66 | ₹47 Cr | — | — |

## Questions and answers

### What is the market cap of Shree Pacetroni?

Shree Pacetroni's market capitalisation is ₹50 Cr (₹50 Cr) at the 22 Oct 2026 close, ranking 3077th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Shree Pacetroni?

Return on equity was 17.4% in FY26 and return on capital employed was 25.0% in FY26 (consolidated figures).

### Is Shree Pacetroni a debt-free company?

No. Shree Pacetroni's debt-to-equity ratio was 0.15 in FY26, with total debt of ₹0 Cr.

### What were Shree Pacetroni's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Shree Pacetroni reported revenue of ₹5 Cr, +25.5% year on year, and net profit of ₹1 Cr, +146.7% year on year.

### What is the shareholding pattern of Shree Pacetroni?

As of 30 Jun 2026: promoters 36.44%, non-institutions 63.56%. 9.44% of promoter shares were pledged.

### Who are Shree Pacetroni's competitors?

The listed Pharma & Healthcare companies closest to Shree Pacetroni by market cap are Bandaram Pharma, Vasundhara Ras, Vivimed Labs, Biofil Chemicals & Pharmaceuticals, Shanmuga Hospit and Mangalam Drugs And Organics.

### Is Shree Pacetroni a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Shree Pacetroni's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SHREEPAC against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.